Tenofovir disoproxil fumarate treatment in HbeAg-positive patients
[ X ]
Tarih
2015
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
EDIMES Edizioni Medico Scientifiche
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Tenofovir disoproxil fumarate (Tenofovir DF) is a nucleotide analogue. This multicentre study reports retrospectively the long-term efficacy and safety data with tenofovir DF treatment in nucleosid(t)e-naive, hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients. Thirty-one patients (11 females, 20 males) received 245 mg tenofovir DF per diem. All patients’ initial serum hepatitis B virus (HBV) DNA levels were over 2,000 IU/ml. Serum alanine aminotransferase (ALT) levels, HBeAg, hepatitis B e antibodies (anti-HBe), hepatitis B surface antigen (HBsAg), hepatitis B surface antibodies (Anti-HBs), HBV DNA, creatinine and urea levels were evaluated at baseline, and at weeks 12, 24, 48 and 96 during therapy. Thirtyone patients completed 96 weeks of treatment. Mean age was 37.6±9.4 years. The initial mean value of ALT was 79±39.9 IU/L. At baseline, mean of fibrosis (Ishak) of liver biopsies was 2.3±0.7. Two of the patients (5.9%) achieved HBV DNA<300 copy at week 12 of treatment and 97.1% at week 96. HBeAg loss was observed in 6.7% of patients. At week 96, HBsAg loss was not observed in any of the patients. Mean ALT at week 48 was 32.7 U/L, at week 96 32.6 U/L. Renal safety was good. Creatinine remained stable. Tenofovir DF was well tolerated and produced potent, continuous viral suppression with increasing HBeAg loss. © 2015, EDIMES Edizioni Medico Scientifiche. All rights reserved.
Açıklama
Anahtar Kelimeler
Hbeag-Positive Chronic Hepatitis B Patients, Nucleosid(T)E-Naive, Tenofovir Disoproxil Fumarate (Tenofovir Df)
Kaynak
Infezioni in Medicina
WoS Q Değeri
Scopus Q Değeri
N/A
Cilt
23
Sayı
1
